🔴 Definium Therapeutics is trading 4.6% down today on technical pullback and broader biotech weakness

Definium Therapeutics is trading 4.6% down at $44.92 as the stock undergoes a technical pullback following its recent rally and broader biotech sector weakness.

• The stock is consolidating after a +6.91% surge on July 9, 2026, which was driven by positive Phase 3 Emerge results for DT120 in major depressive disorder.
• Broader biotech sentiment is negative, with the XBI ETF down over 2% as investors move toward risk-off assets amid escalating U.S.–Iran geopolitical tensions.